Edition:
India

Esperion Therapeutics Inc (ESPR.OQ)

ESPR.OQ on NASDAQ Stock Exchange Global Market

40.33USD
1:30am IST
Change (% chg)

$0.50 (+1.26%)
Prev Close
$39.83
Open
$38.98
Day's High
$40.61
Day's Low
$38.43
Volume
217,307
Avg. Vol
343,435
52-wk High
$82.68
52-wk Low
$33.06

Latest Key Developments (Source: Significant Developments)

Esperion Posts Qtrly Loss Per Share $1.73
Wednesday, 2 May 2018 

May 2 (Reuters) - Esperion Therapeutics Inc ::ESPERION PROVIDES BEMPEDOIC ACID FRANCHISE DEVELOPMENT PROGRAM UPDATES; REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.ESPERION THERAPEUTICS INC - EXPECTS FULL-YEAR 2018 NET CASH USED IN OPERATING ACTIVITIES TO BE APPROXIMATELY $135 TO $145 MILLION.ESPERION THERAPEUTICS - ESTIMATES THAT CURRENT CASH RESOURCES ARE SUFFICIENT TO FUND OPERATIONS THROUGH Q1 OF 2020.ESPERION THERAPEUTICS INC - EXPECTS CASH AND CASH EQUIVALENTS AND INVESTMENT SECURITIES TO BE APPROXIMATELY $130 TO $140 MILLION AT DECEMBER 31, 2018.ESPERION THERAPEUTICS INC QTRLY LOSS PER SHARE $1.73.  Full Article

Esperion Says Phase 3 Long-Term Safety Study Of Bempedoic Acid Met Primary Endpoint
Wednesday, 2 May 2018 

May 2 (Reuters) - Esperion Therapeutics Inc ::ESPERION ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PIVOTAL PHASE 3 LONG-TERM SAFETY STUDY OF BEMPEDOIC ACID.ESPERION THERAPEUTICS INC - STUDY MET PRIMARY ENDPOINT OF SAFETY AND TOLERABILITY IN LARGEST AND LONGEST DURATION STUDY.ESPERION - PATIENTS TREATED WITH BEMPEDOIC ACID ALSO ACHIEVED A SIGNIFICANT REDUCTION OF 22 PERCENT IN HIGH-SENSITIVITY C-REACTIVE PROTEIN.  Full Article

Esperion Announces Positive Top-Line Results From Phase 2 Study Of Bempedoic Acid Added-On To A PCSK9 Inhibitor
Tuesday, 27 Mar 2018 

March 27 (Reuters) - Esperion Therapeutics Inc ::ESPERION ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 2 STUDY OF BEMPEDOIC ACID ADDED-ON TO A PCSK9 INHIBITOR IN PATIENTS WITH HYPERCHOLESTEROLEMIA.ESPERION THERAPEUTICS INC - STUDY MET PRIMARY ENDPOINT WITH 30% ADDITIONAL LDL-C LOWERING.ESPERION THERAPEUTICS INC - BEMPEDOIC ACID ADDED-ON TO A PCSK9 INHIBITOR OBSERVED TO BE SAFE AND WELL-TOLERATED IN THIS STUDY.ESPERION THERAPEUTICS - TO SUBMIT NDAS TO U.S. FDA FOR BEMPEDOIC ACID, BEMPEDOIC ACID/EZETIMIBE COMBINATION PILL FOR LDL-C-LOWERING INDICATIONS BY Q1 2019.  Full Article

Esperion Therapeutics Q3 loss per share $1.86‍​
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Esperion Therapeutics Inc :Esperion provides bempedoic acid franchise development program updates; reports third quarter 2017 financial results.Expects full-year 2017 net cash used in operating activities to be approximately $135 million​.Expects cash and cash equivalents and investment securities to be approximately $272 million at December 31.Estimates cash resources are sufficient to fund operations through Q1 2020​.Qtrly loss per share $1.86‍​.Q3 earnings per share view $-1.78 -- Thomson Reuters I/B/E/S.  Full Article

Esperion announces initiation of pivotal late stage study for bempedoic acid
Tuesday, 7 Nov 2017 

Nov 6 (Reuters) - Esperion Therapeutics Inc :Esperion announces initiation of pivotal late stage study for the bempedoic acid / ezetimibe combination pill.Esperion Therapeutics - ‍NDA submission for LDL-C lowering indication for bempedoic acid / ezetimibe combination pill expected by Q1 2019​.Esperion Therapeutics Inc - ‍top-line results expected by q4 of 2018 for bempedoic acid / ezetimibe combination pill​.  Full Article

Meditor Group Ltd reports 8.2 pct passive stake in Esperion Therapeutics Inc
Monday, 21 Aug 2017 

Aug 21 (Reuters) - Esperion Therapeutics Inc ::Meditor Group Ltd reports 8.2 percent passive stake in Esperion Therapeutics Inc as on Aug 10 - SEC filing​.  Full Article

BB Biotech reports 5.1 pct passive stake in Esperion Therapeutics
Wednesday, 28 Sep 2016 

Esperion Therapeutics Inc :BB Biotech AG reports 5.1 pct passive stake in Esperion Therapeutics as of September 22, 2016 - SEC filing.  Full Article

Esperion Therapeutics reports Q2 net loss of $14 mln
Friday, 5 Aug 2016 

Esperion Therapeutics Inc : Estimates current cash resources are sufficient to fund operations into 2019 . Esperion Therapeutics provides bempedoic acid development program updates; reports second quarter 2016 financial results . Esperion had a net loss of $14.0 million for q2 of 2016 compared to $12.4 million .Esperion expects full-year 2016 net cash used in operating activities in 2016 will be approximately $65 to $75 million.  Full Article

Esperion Therapeutics provides regulatory update for Bempedoic Acid
Wednesday, 29 Jun 2016 

Esperion Therapeutics Inc : Esperion Therapeutics Inc says intends to initiate planned CVOT in statin intolerant patients who are at high risk for CV disease in Q4 of 2016 . Esperion expects full-year 2016 net cash used in operating activities to be between $65 to $75 million . Expects full-year 2016 cash and cash equivalents and investment securities to be approximately $220 million at December 31, 2016 . Current cash resources are expected to be sufficient to fund operations into early 2019 .Esperion Therapeutics provides clinical development and regulatory update for bempedoic acid.  Full Article

Esperion's cholesterol drug safe, effective in new late-stage study

May 23 Esperion Therapeutics said on Wednesday its cholesterol drug was safe and effective in treating heart disease patients in a new late-stage study, weeks after data from an earlier trial raised concerns about the treatment's efficacy.